Trial
NCT05061420
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Merck Sharp & Dohme LLC
Condition
Squamous Cell Carcinoma of Head and Neck
Intervention
Pembrolizumab
Why stopped
Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-22